Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix is reading this filing.
Earlier from Mesoblast
- MSB Reports Increased Revenue and Improved Operating Spend
- FDA Approves New Potency Assay for Commercial Ryoncil
- Annual Report for Fiscal Year Ending June 30, 2026 (Form 20-F)
- Mesoblast Reports Substantial Revenue Growth to US$120M
- Major Milestone Treatment Completed in P3 Trial for CLBP
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast